Hemotune secures CHF 14 Million in Series B2 Funding to advance innovative blood purification technology

Hemotune, a leading Swiss biotech firm renowned for its innovative blood purification solutions, has reached a significant achievement with the closure of a CHF 14 million Series B2 funding round. The investment aims to accelerate the development and commercialization of HemoSystem, hemotune's blood purification platform leveraging nanoengineered magnetic beads.

The Series B2 funding round represents a significant step forward for hemotune, following the successful completion of preclinical development for its HemoSystem blood purification platform. This substantial investment will now allow the platform to move into clinical trials, marking a crucial phase in its development. The investment was led by Belmondo and existing investors including VP Venture Partners, HEMEX, OCCIDENT, Zürcher Kantonalbank, and joined by EFI.

The HemoSystem stands out for its ability to effectively remove large biomolecules directly from patients' bloodstreams, offering a unique approach to implement precision medicine multi-target treatments which would not be possible through drugs. Initially focusing on treating sepsis-related immune suppression, hemotune also plans to explore other potential uses for the platform in the future. Given the serious impact of sepsis, which leads to around 11 million deaths annually and is a major economic burden, the potential benefits of this innovative technology are significant for patients and healthcare systems alike.


hemotune's team